Q2 Holdings Aktie
WKN DE: A1XEYE / ISIN: US74736L1098
08.08.2025 23:22:13
|
Femasys Revenue Jumps 85 Percent in Q2
Femasys (NASDAQ:FEMY), a women’s health medical technology firm developing permanent birth control and fertility solutions, released its second quarter 2025 results on August 8, 2025. The earnings report was marked by strong revenue growth to $0.41 million (GAAP)—an 84.8% jump in GAAP sales from the prior year period—driven by accelerating early-stage sales of FemaSeed intratubal insemination devices and FemVue diagnostic systems. This figure (GAAP revenue of $409,268) came in far above analyst estimates. The company posted a GAAP net loss of $4.59 million, a slight improvement from the $4.68 million GAAP net loss in Q2 2024. Diluted earnings per share (GAAP) was slightly better than analyst estimates at $(0.16). Despite clear commercial and regulatory progress, continued operating losses and a $3.22 million cash balance as of June 30, 2025 mean Femasys will need additional funding within the next quarter to sustain operations. Source: Analyst estimates for the quarter provided by FactSet. Femasys designs and commercializes non-surgical products for women’s reproductive health needs. Its main portfolio spans permanent birth control devices—most notably the FemBloc system—and fertility-related solutions like FemaSeed and FemVue.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Q2 Holdings Incmehr Nachrichten
29.07.25 |
Ausblick: Q2 veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
06.05.25 |
Ausblick: Q2 legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) |
Analysen zu Q2 Holdings Incmehr Analysen
Aktien in diesem Artikel
Femasys Inc Registered Shs | 0,49 | 18,10% |
|
Q2 Holdings Inc | 56,50 | 0,00% |
|